Mereo BioPharma Group plc (MREO) Form 8-K — Nov 9, 2026
Mereo BioPharma reported Q3 2026 results with a net loss of $5.9 million, improved from $7.0 million a year earlier, as R&D spending was cut to $2.1 million from $4.3 million and G&A fell to $4.9 million from $6.0 million. Cash stands at $26.1 million versus $41.0 million at year-end 2025, which the company says funds operations into late-2027 — but that runway excludes the potential $40 million in upfront and R&D payments if Sentynl exercises its alvelestat option.
Key figures
- Revenue
- 800000
- Total Debt
- 0
- Total Assets
- 29583000
- Cash Position
- 26100000
- Shares Outstanding
- 798454864
- Cash dec 31 2025
- 40992000
- Q3 2025 net loss
- 7024000
- Q3 2025 ga expense
- 6045000
- Q3 2026 ga expense
- 4928000
- Q3 2025 rnd expense
- 4270000
- Q3 2026 rnd expense
- 2090000
- Nine month 2026 net loss
- 19587000
- Ads equivalents outstanding
- 159690972
- Sentynl milestones potential
- 435000000
- Sentynl upfront and rd payments potential
- 40000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.